CEO Jessica Grossman will be presenting at the 5th Annual Antigen-Specific Immune Tolerance Drug Development Summit. Jessica and others in the life science community will discuss and identify therapeutic opportunities in 2022. https://t.co/aOztBqv3c2
We reviewed #lungcancer#ctDNA#MRD data here with a focus on clinical sensitivity and specificity for predicting relapse. Hope this is a great resource to the #liquidbiopsy field.
Our own Jessica Grossman will represent the IgGenix team and speak at the @LongwoodFund Healthcare Leaders Winter Meeting. Jessica will be sharing more insight into IgGenix's allergy research and treatments. https://t.co/rLgwCCrDHJ